Shu Jian-chang, Ye Guo-rong, Lü Xia, Fang Li, Wu Hai-en, Chen Xiao-juan
Department of Gastroenterology, Affiliated Guangzhou Red Cross Hospital of the Medical College of Jinan University, Guangzhou 510220, China.
Zhonghua Gan Zang Bing Za Zhi. 2007 Oct;15(10):753-7.
To investigate the therapeutic effects and mechanisms of curcumin treatment on hepatic fibrosis.
A model of hepatic fibrosis was established using carbon tetrachloride intraperitoneal injections in rats. Curcumin was administered to one group of the model rats (curcumin group) and the other rats were used as controls (control group). Serum levels of ALT, AST, HA, LN, PCIII, and NO were measured, and Hyp, MDA, and SOD in liver tissues were measured. Liver tissue slides were stained with HE and Masson staining to study the pathological changes in the livers. Grades of hepatic fibrosis were evaluated according to a semiquantitative scoring system.
In the curcumin group, serum levels of ALT, AST, NO, HA, LN, PCIII, MDA, and Hyp, were (218.50+/-48.89) U/L, (376.60+/-79.13) U/L, (47.96+/-6.53) micromol/L, (289.96+/-60.43) mg/L, (107.35+/-27.24) mg/L, (148.95+/-28.63) microg/L, (236.10+/-30.54) nmol/g, (478.40+/-75.74) microg/g and all were lower than those of the control group (693.75+/-117.57) U/L, (892.50+/-105.69) U/L, (70.95+/-10.23) micromol/L, (468.22+/-93.45) mg/L, (346.44+/-75.08) mg/L, (279.82+/-54.00) microg/L, (402.25+/-39.16) nmol/g, and (752.50+/-77.62) microg/g. The differences were significant. In the curcumin group, the level of SOD (90.39+/-21.23) in the liver tissues was significantly higher than that of the control group (46.52+/-20.01). The hepatic fibrosis scores in the curcumin group were significantly lower than those of the control group. These effects were dose-dependent.
Curcumin reduces rat hepatic fibrosis. Anti-peroxidation and regulation of collagen metabolism in liver tissues may be involved in the therapeutic effectiveness of curcumin on hepatic fibrosis.
探讨姜黄素治疗肝纤维化的疗效及机制。
采用四氯化碳腹腔注射法建立大鼠肝纤维化模型。将一组模型大鼠给予姜黄素（姜黄素组），另一组大鼠作为对照（对照组）。检测血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原（PCIII）和一氧化氮（NO）水平，并测定肝组织中羟脯氨酸（Hyp）、丙二醛（MDA）和超氧化物歧化酶（SOD）含量。肝组织切片进行苏木精-伊红（HE）染色和Masson染色，以研究肝脏的病理变化。根据半定量评分系统评估肝纤维化分级。
姜黄素组血清ALT、AST、NO、HA、LN、PCIII、MDA和Hyp水平分别为（218.50±48.89）U/L、（376.60±79.13）U/L、（47.96±6.53）μmol/L、（289.96±60.43）mg/L、（107.35±27.24）mg/L、（148.95±28.63）μg/L、（236.10±30.54）nmol/g和（478.40±75.74）μg/g，均低于对照组的（693.75±117.57）U/L、（892.50±105.69）U/L、（70.95±10.23）μmol/L、（468.22±93.45）mg/L、（346.44±75.08）mg/L、（279.82±54.00）μg/L、（402.25±39.16）nmol/g和（752.50±77.62）μg/g。差异有统计学意义。姜黄素组肝组织中SOD水平（90.39±21.23）明显高于对照组（46.52±20.01）。姜黄素组肝纤维化评分明显低于对照组。这些作用呈剂量依赖性。
姜黄素可减轻大鼠肝纤维化。姜黄素对肝纤维化的治疗作用可能与其抗过氧化及调节肝组织胶原代谢有关。
